Placebo to match cilofexor

DRUG2 trials

Sponsors

Gilead Sciences

Conditions

Primary Biliary CholangitisPrimary Sclerosing Cholangitis

Phase 2

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

CompletedNCT02943460

Gilead SciencesPrimary Sclerosing Cholangitis

Start: 2016-11-29End: 2020-05-18Updated: 2021-06-07

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis

TerminatedNCT02943447

Gilead SciencesPrimary Biliary Cholangitis

Start: 2016-12-01End: 2019-09-04Updated: 2020-09-22

Related Papers

Breaking Grounds: A Comprehensive Analysis of Cutting-Edge Treatments for Primary Biliary Cirrhosis/Primary Biliary Cholangitis With Futuristic Treatments.

2025-02-24

Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B Study

Clinical and Translational Gastroenterology2024-07-013 citations

Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.

2022-08-0427 citations